The Study
1690-P: PG-110, a Novel Bispecific Antibody Targeting ActRII and Myostatin, Enhances Fat-Specific Weight Loss and Improves Bone Health in Combination with GLP-1 Agonist Therapy
This study looked at how two medicines affected mice that were overweight. It saw that their fat went down and bones got stronger, but it didn't compare them fairly to other mice or prove the medicines caused those changes. So we can only say what happened in these mice — not that it would work the same in people.
Analysis score
Maximum 72 for a cohort study.
Where the score came from
Scientists gave obese mice a weight-loss drug (semaglutide) and a new antibody (PG-110) to see if they could lose more fat without losing muscle or bone.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 516 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1If this works in humans, it could help people lose fat while keeping muscle and bone strong — important for staying healthy and active during weight loss.
- 2Mice that got both drugs lost more fat and lost weight faster than mice that got only semaglutide.
- 3Their muscle stayed the same, and their leg bones got stronger.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Diabetes
Year
2025
Authors
Younglim Son, Seung-Ah Lee, Jong-Gyun Kim, Sang-In Yang, Youngchul Sung
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.